drugset / Trial / NCT05068427
Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the preliminary efficacy and safety of Chidamide combined with Envafolimab in patients with PD-1 inhibitor resistant advanced NSCLC.
Timeline
- Start
- 2021-11-23
- Primary completion
- 2023-02-23
- Completion
- 2024-05-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Envafolimab | Monoclonal antibody | 400 mg | Subcutaneous |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |